Cannabis Law Report

SEPTEMBER 23, 2022

Going forward, MAPS will focus on advocating for psychedelic policy reform to include state funding for public education, harm reduction, and unarmed crisis response services. The continued criminalization of all drugs and the people who use them increases harms to public health and safety. ABOUT MAPS.

Decriminalization 52

Decriminalization Advocacy Research and Development Education 52

Cannabis Law Report

JUNE 4, 2021

– Drug Demonstrates Efficacy and Safety in Advanced Prostate Cancer Patients. – Phase 2 Trial Underway. Additionally, this novel antibody conjugate demonstrated very good tolerability during this DLT phase 1 trial. Clinical trial information: NCT03276572 ( [link] ). Abstract Number: 5015.

Data 100

Data Research and Development Clinical Trials Therapy 100

Cannabis Law Report

JULY 1, 2021

Clinical trials repeatedly demonstrate their promise for treating mood, anxiety, and substance use disorders. POPLAR is the first academic initiative focused on psychedelics law and policy, positioned to be a global leader for research and education in this space. Background. The Project.

Law 59

Law Policy Research and Development Clinical Trials 59

The Cannigma

AUGUST 31, 2021

Medical societies are slowly providing more CME (continuing medical education) to doctors on cannabis, however, that educational content tends to be slanted toward risk mitigation. Fortunately, there is a slowly growing community of cannabis physicians who are learning through trial and error and from one another.

Education 101

Education Clinical Trials Medicine Policy 101

Cannabis Law Report

JUNE 10, 2021

The Traffic Safety Culture Index is an annual survey with national scope and multiple measures relevant to driving after marijuana use. Because THC presence is an imperfect proxy for impairment [ 10 ], driving data may be limited in clarifying what traffic safety risks, if any, are associated with permissive marijuana policies.

Policy 59

Policy Safety Marijuana Data 59

The Blunt Truth

DECEMBER 23, 2020

assured, “The FDA’s first priority is to protect the health and safety of Americans. In its announcement of the warning letters, FDA Principal Deputy Commissioner Amy Abernethy, M.D., Actions Speak Louder Than Words.

CBD 103

CBD Food Safety Clinical Trials 103

Cannabis Law Report

JULY 28, 2021

We believe in diversity and inclusion of people of all backgrounds, genders, races, ethnicities, sexual orientations, educational backgrounds, military and veteran status,?religions, 2-3 years of relevant experience in clinical trials, research methods, or statistical design and analysis. religions, abilities, and perspectives.

Clinical Trials 105

Clinical Trials Research and Development Data Environment 105

TheAnswerPage

JANUARY 11, 2022

As the Editor-in-Chief of the medical education website called TheAnswerPage.com for nearly two decades, I have assessed multiple educational gaps in the healthcare community. Thus, an educational gap developed, creating a less than ideal situation for medical marijuana patients. So, why did this educational gap develop?

Patients 98

Patients Education Marijuana Therapy 98

Veriheal

AUGUST 31, 2020

At Veriheal, education and diversity are at the center of our core values. Choosing only 10 winners for the $10,000 in scholarships among the strong applications we received from multiple disciplines and concentrations in higher education—from students of all backgrounds and interests—was extremely difficult.

Research and Development 117

Research and Development Education Agriculture Patients 117

Cannabis Law Report

AUGUST 21, 2019

However, health professionals have been reluctant to prescribe cannabis-based medicines in the UK because of the lack of clinical trial evidence of its benefits and safety. This would answer questions about safety and efficacy, they said. The final guideline is expected to be published in November 2019.

Clinical Trials 81

Clinical Trials Nerve Pain Medicine Epilepsy 81

The Cannigma

DECEMBER 14, 2021

There are no published studies on the efficacy or safety of HHC in human subjects but that has not stopped some manufacturers from producing and selling HHC products. This would indicate that similar to THC, HHC is metabolized in humans to 11-hydroxy-HHC which could in part be responsible for the psychoactive effects of HHC when consumed.

Research and Development 116

Research and Development Cannabinoids Clinical Trials THC 116

Miss Marijuana

JUNE 30, 2019

As the industry leader, we are committed to advancing research and education to help more and more consumers realize the many benefits of hemp CBD supplementation.”. So what’s next? Our health and wellness depends on it!

Sleep 72

Sleep CBD Clinical Trials Oil 72

SpeedWeed

JULY 6, 2021

The Project on Psychedelics Law and Regulation (POPLAR) is a three-year project aiming to “promote safety, innovation, and equity in psychedelics research, commerce, and therapeutics,” the university said in a press release.

Policy 52

Policy Law Research and Development Therapy 52

Cannabis Law Report

DECEMBER 2, 2021

Under the approved recommendations, students applying for psilocybin training programs are required to provide a description of their educational background and a written statement explaining their commitment and interest in becoming a psilocybin facilitator. Safety, Ethics and Responsibilities of a Psilocybin Facilitator (10 Hours).

Law 52

Law Programs Therapy Education 52

Cannabis Law Report

JUNE 4, 2021

Titus then went on to earn his PhD from Open International University, an educational organization affiliated with the World Health Organization. Dr. Titus holds a Fellowship with the American Academy of Pain Management and clinical association with the American Association of Integrative Medicine. for CS First Boston Corp.

Research and Development 105

Research and Development Seed-To-Sale Cannabinoids THC 105

Cannabis Law Report

JUNE 25, 2021

The European Medicines Agency (EMA) is the regulatory body that evaluates and supervises the production and sales of medicines for safety and benefit of the customer, in the European Union Region. Celgene was founded in 1986 and is headquartered at Summit, New Jersey, United States.

Research and Development 84

Research and Development Therapy Pharmaceutical Clinical Trials 84

Cannabis Law Report

AUGUST 19, 2019

Additionally, doctors generally do not feel well-educated around the use of medicinal cannabis products, with specialists often feeling that there is inadequate evidence to support their use in specific conditions. Despite this, many tens of thousands of Australians continue to self-medicate with illicit medicinal cannabis.

Medicine 45

Medicine Patients Clinical Trials Access 45

Healer

DECEMBER 17, 2021

The safety profile of CBD has been acknowledged by major health agencies, such as the World Health Organization (WHO), showing that it’s well-tolerated by animals and humans and rarely produces any dangerous side effects. Numerous studies have shown that CBD is a safe, non-impairing, and non-habit-forming substance.

CBD 98

CBD THC Conditions Medicine 98

The Cannigma

AUGUST 26, 2021

This also means that the TGA has not accessed these medicines for their safety, quality, or effectiveness. These products can only be accessed through the Special Access Scheme by an authorized healthcare practitioner, or as part of a clinical trial, according to the Office of Drug Control. Costs of medical marijuana.

Legalization 52

Legalization Access Medicine Clinical Trials 52

Cannabis Law Report

JULY 4, 2021

Clinical trials across the EU have also shown CBD oils and other hemp products to have a potential range of benefits. The Cannabis Trade Association works to improve and maintain health, safety and environmental regulations and practices around cannabis industries. Final Note.

THC 105

THC CBD Legalization Oil 105

Cannabis Law Report

JANUARY 11, 2019

However, we firmly disagree that the referenced clinical trials are in fact “substantial,” as the trials were extremely limited in scope, and funding and the publication of these trials were limited. CBD has been found to be generally well tolerated with a good safety profile.”. 1] [link]. [2] 2] [link]. [3]

Hemp 49

Hemp CBD Law Seed-To-Sale 49

Kind Meds (Cannabis Education Blog)

JANUARY 9, 2019

Thanks to their diligence in perfecting the drug and ensuring its safety for intended use, the Drug Enforcement Agency scheduled Epidiolex under the lowest Schedule classification for controlled substances. GW Pharma carefully developed Epidiolex using cannabinoids to reduce the occurrence of seizures. What You Should Know About Epidiolex.

Research and Development 97

Research and Development Treatment Pharmaceutical Conditions 97

Cannabis Law Report

DECEMBER 20, 2021

(“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, signed a clinical trial agreement with Altasciences Company, Inc.,

Clinical Trials 52

Clinical Trials Chronic Pain Pharmaceutical Data 52

Healer

DECEMBER 17, 2021

The safety profile of CBD has been acknowledged by major health agencies, such as the World Health Organization (WHO), showing that it’s well-tolerated by animals and humans and rarely produces any dangerous side effects. Numerous studies have shown that CBD is a safe, non-impairing, and non-habit-forming substance.

CBD 52

CBD THC Conditions Medicine 52

The Cannigma

JUNE 15, 2021

But the main issue with hemp derived products and their safety is less about the CBD and more about everything else in them. The main safety issues with CBD are drug interactions, and unsafe manufacturing processes due to the unregulated environment. . But that doesn’t make it completely risk free. Kevin McGovern/Shutterstock).

CBD 122

CBD Research and Development Epilepsy Extraction 122

Project CBD

FEBRUARY 28, 2023

The following excerpt analyzes CBD marketing trends reported by the American Botanical Council, a membership organization that educates consumers, health care professionals, journalists, and others about the safe and effective use of medicinal plants. (E-commerce sales of CBD in the U.S. in 2021 reached $2 billion, according to Statistica.)

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

JANUARY 26, 2022

The Innovation Passport does not reduce the burden of demonstrating that a treatment may be safe and effective, but does provide research organizers with expert advice, patient input, and collaboration throughout the clinical trial design and development process through a product-specific Target Development Profile.

Therapy 52

Therapy Clinical Trials Research and Development Treatment 52

Cannabis Law Report

APRIL 8, 2022

This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. MAPS completed the first Phase 1 safety study with MDMA and resumed working on a protocol for anxiety associated with cancer.

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Cannabis Law Report

JULY 28, 2021

Cepharanthine is on its way to establishing itself as a once per day, oral anti-cancer therapeutic with a well-established safety profile which will pave the way for an expedited clinical development pathway and future partnering opportunities with pharmaceutical companies. ” Next Steps. ” Next Steps. dcohen@pharmadrug.co.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

CannaMD

MARCH 8, 2021

Read on to learn why CannaMD is leading the charge with other physician groups to educate legislators and oppose H.B. Authorizing the department to sample marijuana delivery devices from a dispensing facility to determine safety [p. 1455 – and how YOU can fight back with research-based arguments! 1, line 14]. 1, line 17]. 1, line 19].

THC 116

THC Research and Development Treatment Patients 116

The Cannigma

MARCH 12, 2021

MSO: So much of that has to do with the lack of education among medical professionals, but also the lack of scientific information, saying which cannabis products are good for what symptoms or what conditions and hopefully, we get there one day. And in my belief, it should be cannabis, because of the safety profile, number one.

Legalization 128

Legalization Patients Education Dispensary 128

Peninsula Alternative Health

MAY 15, 2019

The huge difference between medical cannabis and traditional pharmaceuticals is that cannabis is quickly becoming accessible to treat conditions before clinical trials and standard dosing protocols have been established. This cannot be said for most if any prescribed or over the counter medicines on today's market. References Staff, T.

Conditions 89

Conditions Therapy Cannabinoids Epilepsy 89

The Cannigma

APRIL 8, 2021

With cannabis, Dr. Peterson, continues, your best source of education is often a budtender with nothing more than a high school education. They can only refer you, and then you get sent to someone with potentially just a high school education. Sorry, that’s important, safety window. Dr. Codi Peterson, PharmD.

Medicine 108

Medicine Cannabinoids Cannabis THC 108

Cannabis Law Report

MARCH 29, 2020

At an HIV Community Cannabis Education event held in Toronto, a cannabis company proudly declared their company had not had a single product recall to date. This post explores the manufacturing and research standards to consider when conducting research studies with cannabis. . . Product Quality in Manufacturing.

Compliance 69

Compliance Compliance Supply Chain Research and Development 69

Cannabis Law Report

NOVEMBER 24, 2021

However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. Framings that more often carried a negative tone were related to poor evidence and safety issues.

Research and Development 52

Research and Development Medicine Access Media 52

Peninsula Alternative Health

MAY 15, 2019

The huge difference between medical cannabis and traditional pharmaceuticals is that cannabis is quickly becoming accessible to treat conditions before clinical trials and standard dosing protocols have been established. This cannot be said for most if any prescribed or over the counter medicines on today's market. References Staff, T.

Conditions 40

Conditions Therapy Cannabinoids Epilepsy 40

Cannabis Law Report

MAY 13, 2019

5 ] Subsequently, generations of health professionals were educated in a system where cannabis was considered purely illicit. For instance, it has been very challenging to perform clinical trials on herbal cannabis due to the enduring illicit status of cannabis across much of the world.

Medicine 45

Medicine Research and Development Clinical Trials Data 45